Pacific Biosciences
PACB
272 hedge funds and large institutions have $3.37B invested in Pacific Biosciences in 2023 Q2 according to their latest regulatory filings, with 45 funds opening new positions, 99 increasing their positions, 64 reducing their positions, and 30 closing their positions.
87% more call options, than puts
Call options by funds: $47.5M | Put options by funds: $25.4M
55% more repeat investments, than reductions
Existing positions increased: 99 | Existing positions reduced: 64
50% more funds holding in top 10
Funds holding in top 10: 4 → 6 (+2)
50% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 30
15% more capital invested
Capital invested by funds: $2.93B → $3.37B (+$444M)
5% more funds holding
Funds holding: 259 → 272 (+13)
1% less ownership
Funds ownership: 102.55% → 101.55% (-1%)
Top Buyers
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$24.1M |
| 2 |
Millennium Management
New York
|
+$15.8M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$12.1M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$10.3M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
+$10.3M |
Top Sellers
| 1 |
JSP
Jackson Square Partners
Larkspur,
California
|
-$43.5M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$25M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
-$16.9M |
| 4 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$15.1M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$13.7M |
PACB Hedge Fund Activity: Q2 2023 in Review
272 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Pacific Biosciences (PACB) for Q2 2023, worth a combined $3.37B — up 15% from $2.93B a quarter earlier.
Buyers outnumbered sellers: 45 funds opened new PACB positions and 30 closed out — a net gain of 15 holders — while 99 added to existing stakes and 64 trimmed.
The largest buyer was Farallon Capital Management, adding an estimated $24.1M. The largest seller was Jackson Square Partners, cutting an estimated $43.5M.
- 272 institutional investors held Pacific Biosciences (PACB) as of Q2 2023, up from 259 in Q1 2023.
- Funds reported $3.37B of Pacific Biosciences stock for Q2 2023, up 15% quarter-over-quarter.
- 45 funds opened new Pacific Biosciences positions in Q2 2023 and 30 closed out, a net change of +15 holders.
- The largest Pacific Biosciences buyer in Q2 2023 was Farallon Capital Management, an estimated $24.1M added.
- The largest Pacific Biosciences seller in Q2 2023 was Jackson Square Partners, an estimated $43.5M sold.
Based on aggregated 13F filings for Q2 2023.